1998
DOI: 10.1016/s0161-5890(98)90790-8
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic intervention with complement and complement receptors in cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
4
0

Year Published

1999
1999
2013
2013

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(4 citation statements)
references
References 0 publications
0
4
0
Order By: Relevance
“…The identity of the ␤ -glucan receptor, which has been defined as a ␤ -glucan inhibitable receptor for particulate activators of the alternative complement pathway (6), is controversial. The ability of CR3 to recognize ␤ -glucans led to the proposal that this receptor is the major ␤ -glucan receptor on leukocytes and that it mediates all the immunomodulatory effects of these carbohydrates, including the ␤ -glucan-dependent binding of zymosan (4,(9)(10)(11). Conflicting evidence, however, indicated that another receptor(s) mediates this activity (6,(12)(13)(14), and although we and others have identified additional receptors capable of recognizing ␤ -glucans (15)(16)(17), their role in primary cells is unclear.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…The identity of the ␤ -glucan receptor, which has been defined as a ␤ -glucan inhibitable receptor for particulate activators of the alternative complement pathway (6), is controversial. The ability of CR3 to recognize ␤ -glucans led to the proposal that this receptor is the major ␤ -glucan receptor on leukocytes and that it mediates all the immunomodulatory effects of these carbohydrates, including the ␤ -glucan-dependent binding of zymosan (4,(9)(10)(11). Conflicting evidence, however, indicated that another receptor(s) mediates this activity (6,(12)(13)(14), and although we and others have identified additional receptors capable of recognizing ␤ -glucans (15)(16)(17), their role in primary cells is unclear.…”
Section: Introductionmentioning
confidence: 99%
“…Zymosan is a yeast-derived particle composed principally of polysaccharides, of which ␤ -glucan, the active component mediating the cellular effects (2), and mannan are the major constituents (3). In vivo administration of zymosan, or purified soluble ␤ -glucans, has a number of desirable effects on immune function, including the ability to confer resistance to tumors and various infections, prompting interest in the development of ␤ -glucanbased therapeutics (4,5). Despite the significant therapeutic implications, the molecular mechanism through which these effects are mediated is not known.…”
Section: Introductionmentioning
confidence: 99%
“…The C3b cleavage fragment (iC3b) serves as a receptor of natural killer (NK) cells, which are the most potent, tumoreliminating, immune weapon of the host. MT1-MMP, by shedding iC3b from the cell surface, interferes with anticancer cellular immunity (23). Consequently, MT1-MMP inhibits the complement cascade and protects tumor cells from complement-mediated injury.…”
Section: Introductionmentioning
confidence: 99%
“…β-1,3/1,6-D-glucan obtained from the yeast is known as a natural immunostimulant. β-D-glucans affect selected receptors that among others include CD11b/CD18 (CR3), lactosylceramide, scavenger receptors and TLR2 (toll-like receptor 3), TLR4 by activating macrophages, phagocytes and T-helper lymphocytes (Ross et al 1999). They stimulate phagocytes for the production of cytokines IL-1, IL-9, TNF-α, as well as affect the synthesis of acute-phase proteins, including ceruloplasmin .…”
mentioning
confidence: 99%